QGEN Qiagen NV

According to my data: About 41% of the biggest stocks' volume traded away from the exchanges on Thursday, Oct 22. The 10 largest off-exchange names were mostly down that day (1 of 10 rose). Most unusual: $QGEN traded 14.0x its normal off-exchange volume on a +0.4% day; 12 big stocks were at 1.5x or more. Unusually dark: $STX 58%, $MRNA 53%, $GEV 53% of volume off-exchange, where big buyers and sellers hide size. In the latest dark-pool week, $SPY led (+17% week over week). There are some interesting things happening behind the scenes.

$QGEN Friday's 6.5% pop to 44.75 wasn't the FDA headline. It was the Betaville "uncooked" alert traders were passing around: at least one potential buyer is in advanced talks to acquire Qiagen at a "realistic premium." The scaffolding is real. Qiagen has had Moelis and Goldman Sachs running a strategic review since March. CTFN said two parties entered formal due diligence in August. The names linked along the way: KKR, EQT, Advent, TPG, Bain. Manager Magazin reported Qiagen wants at least 50 a share. From Friday's close, that's about a 12% premium. Underneath it was a real product beat too: the FDA cleared the QIAstat-Dx gram-negative sepsis panel on Sept 28, completing the bloodstream-infection menu at 33 pathogen targets and 28 resistance markers, all inside an hour. The 2020 precedent: Thermo Fisher walked away from a 43-euro offer when shareholders rebelled. Landing the premium is one thing; getting holders to accept it is another.

Two bidders and $QGEN still has not priced the over $50 offer in full EQT put in a binding bid over $50, KKR bid too, board meets this week per Reuters it jumped over 6 percent Tuesday on 5.9 times normal volume and is holding near $48.83 this morning. two buyers for a diagnostics name usually means the first number is not the last one imo

$QGEN QIAGEN agrees to a €46.50-a-share cash buyout led by EQT, about €10.8bn EV. 🏢 Dutch maker of DNA/RNA sample-prep tools and molecular diagnostic tests 🤝 40.3% premium to the €33.15 XETRA close of July 8, 2026, before buyout-interest reports 🏢 10.85bn-dollar market value at $50, 16:00 ET Oct 21, 2026 (Dec 31, 2025 shares); EV ~$12.1bn incl. ~$1.1bn net debt ⚠️ Needs 50% plus one share tendered, an EGM vote, and merger-control and foreign-investment clearances 📅 Next: Offer document follows BaFin clearance; closing expected in mid-2027 Source: SEC SC 14D-9C + QIAGEN/EQT release, Oct 21

Someone wants to buy Qiagen, and traders noticed. A fresh report says takeover talks for the diagnostics giant are heating up, and $QGEN is up 7% today. Mystery buyer, premium pending.

BRZEMMM $QGEN — three volume spikes, three different stories. **$BRZE:** +51.7%, volume 32.7x. Salesforce buying Braze for $47.50/share cash ($5.66B deal). Closed at $45.57 — market pricing the deal, not the business. Insider selling irrelevant in M&A. $MMM: +5.0%, volume 4.5x. Q3 beat + Amazon deal for data-center optics. Options flow 3.1/10, P/C 1.18 (hedging). Real operating story. **$QGEN:** +5.05%, volume 3.49x. Bloomberg: EQT in advanced talks to buy above $50/share. KKR also interested. Board meets this week. Deal rumor, not business story. One done deal, one real news, one rumor. Same volume pattern. NFA.